rediff.com

Alembic Gets USFDA Nod for Generic Anti-Epileptic Drug

Share on:

By Rediff Money Desk, New Delhi   Dec 20, 2024 16:30

Alembic Pharmaceuticals receives USFDA approval for generic Divalproex Sodium delayed-release capsules, a treatment for epilepsy. The drug is therapeutically equivalent to Depakote Sprinkle capsules.
Alembic Gets USFDA Nod for Generic Anti-Epileptic Drug
New Delhi, Dec 20 (PTI) Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy.

The approval granted by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) of Divalproex Sodium delayed-release capsules of strength 125 mg, Alembic Pharmaceuticals said in a regulatory filing.

The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Depakote Sprinkle capsules, 125 mg of AbbVie Inc, it added.

Divalproex Sodium is an anti-epileptic drug indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures, it added.

Citing IQVIA data, the company said Divalproex Sodium delayed-release capsules 125 mg have an estimated market size of USD 61.1 million for 12 months ended September 2024.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

More »

Moneywiz Live!